{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Sir+Paul+Beresford&session.=2015%2F16", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMember.label=Biography+information+for+Sir+Paul+Beresford&session.=2015%2F16", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Sir+Paul+Beresford&session.=2015%2F16&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Sir+Paul+Beresford&_page=0&session.=2015%2F16", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Sir+Paul+Beresford&session.=2015%2F16", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Sir+Paul+Beresford&session.=2015%2F16", "items" : [{"_about" : "http://data.parliament.uk/resources/516698", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/516698/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence (NICE) has approved a number of different treatments for psoriasis as part of its technology appraisal (TA) programme, the most recent of these being Secukinumab, which was recommended as a possible treatment for people with plaque psoriasis in July 2015. The National Health Service is legally obliged to fund medicines and treatments recommended by NICE's TA programme, meaning people can access these treatments wherever they live in the country.<\/p>
Information regarding the cost to the NHS of the continued treatment of psoriasis patients who do not achieve 75% skin clearance is not collected. The NICE best practice guideline Psoriasis: assessment and management, <\/em>published in October 2012, covers approaches to diagnosis and treatment and specialist referral. The majority of TA recommended psoriasis treatments are featured in the guideline, and their success in treating psoriasis is measured using Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index. PASI is a quantitative rating score for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. In most cases, NICE defines an adequate response to treatment as one that includes a 75% reduction in a PASI score. The NICE guidance can be found at the following link:<\/p> www.nice.org.uk/guidance/cg153/resources/psoriasis-assessment-and-management-35109629621701<\/a><\/p> For patients who do not responded adequately to either topical treatment or biological therapies, such as those recommended by the NICE TA programme, the guidance recommends referral to a specialised service. NHS England commissions specialised dermatology services nationally and has set out what providers must have in place in order to deliver specialised dermatology care, as well as defining referral criteria. For psoriasis patients, referrals are appropriate where their condition is severe and they have not responded to NICE approved biological therapies. More information on specialised dermatology services can be found at the following link:<\/p> www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
}
, "answeringMemberConstituency" : {"_value" : "Battersea"}
, "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
, "dateOfAnswer" : {"_value" : "2016-05-04", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "36026"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-05-04T11:42:07.153Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2016-04-28", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Psoriasis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what the cost to the public purse is of NHS psoriasis patients continuing their current treatment who do not reach the NICE goal of 75 per cent skin clearance from treatment start.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/103", "label" : {"_value" : "Biography information for Sir Paul Beresford"}
}
, "tablingMemberConstituency" : {"_value" : "Mole Valley"}
, "tablingMemberPrinted" : [{"_value" : "Sir Paul Beresford"}
], "uin" : "36027"}
, {"_about" : "http://data.parliament.uk/resources/516700", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/516700/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) has approved a number of different treatments for psoriasis as part of its technology appraisal (TA) programme, the most recent of these being Secukinumab, which was recommended as a possible treatment for people with plaque psoriasis in July 2015. The National Health Service is legally obliged to fund medicines and treatments recommended by NICE's TA programme, meaning people can access these treatments wherever they live in the country.<\/p> Information regarding the cost to the NHS of the continued treatment of psoriasis patients who do not achieve 75% skin clearance is not collected. The NICE best practice guideline Psoriasis: assessment and management, <\/em>published in October 2012, covers approaches to diagnosis and treatment and specialist referral. The majority of TA recommended psoriasis treatments are featured in the guideline, and their success in treating psoriasis is measured using Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index. PASI is a quantitative rating score for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. In most cases, NICE defines an adequate response to treatment as one that includes a 75% reduction in a PASI score. The NICE guidance can be found at the following link:<\/p> <\/p> <\/p> <\/p> <\/p> <\/p> <\/p> <\/p> Counts of Finished Admission Episodes (FAEs)1<\/sup> for dog bites and strikes2<\/sup>, 2009-10 to 2013-143<\/sup><\/strong><\/p> <\/p> <\/p> <\/p> Activity in English NHS Hospitals and English NHS commissioned activity in the independent sector<\/p> <\/p> Year<\/strong><\/p><\/td> FAEs<\/strong><\/p><\/td><\/tr> 2009-10<\/p><\/td> 5,837<\/p><\/td><\/tr> 2010-11<\/p><\/td> 6,005<\/p><\/td><\/tr> 2011-12<\/p><\/td> 6,580<\/p><\/td><\/tr> 2012-13<\/p><\/td> 6,317<\/p><\/td><\/tr> 2013-14<\/p><\/td> 6,836<\/p><\/td><\/tr><\/tbody><\/table> <\/p> Source: Hospital Episode Statistics (HES), Health and Social Care Information Centre<\/p> <\/p> <\/p> <\/p> 1. Finished admission episodes A finished admission episode (FAE) is the first period of admitted patient care under one consultant within one healthcare provider. FAEs are counted against the year or month in which the admission episode finishes. Admissions do not represent the number of patients, as a person may have more than one admission within the period.<\/p> <\/p> 2. External cause codes<\/p> <\/p> A supplementary code that indicates the nature of any external cause of injury, poisoning or other adverse effects. Only the first external cause code which is coded within the episode is counted in HES.<\/p> <\/p> <\/p> <\/p> ICD-10 code used: W54 - Bitten or struck by dog<\/p> <\/p> <\/p> <\/p> 3. Assessing growth through time (Admitted patient care)<\/p> <\/p> HES figures are available from 1989-90 onwards. Changes to the figures over time need to be interpreted in the context of improvements in data quality and coverage (particularly in earlier years), improvements in coverage of independent sector activity (particularly from 2006-07) and changes in NHS practice. For example, apparent reductions in activity may be due to a number of procedures which may now be undertaken in outpatient settings and so no longer include in admitted patient HES data. Conversely, apparent increases in activity may be due to improved recording of diagnosis or procedure information.<\/p> Note that Hospital Episode Statistics (HES) include activity ending in the year in question and run from April to March, e.g. 2012-13 includes activity ending between 1st April 2012 and 31st March 2013.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3934", "label" : {"_value" : "Biography information for George Eustice"}
}
, "answeringMemberConstituency" : {"_value" : "Camborne and Redruth"}
, "answeringMemberPrinted" : {"_value" : "George Eustice"}
, "dateOfAnswer" : {"_value" : "2015-06-08", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-06-08T16:22:15.063Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "13"}
, "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"}
, "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"}
, "date" : {"_value" : "2015-06-03", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Dangerous Dogs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Environment, Food and Rural Affairs, how many deaths and injuries have been caused by prohibited animals which are (a) not on and (b) on the Index of Exempted Dogs in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/103", "label" : {"_value" : "Biography information for Sir Paul Beresford"}
}
, "tablingMemberConstituency" : {"_value" : "Mole Valley"}
, "tablingMemberPrinted" : [{"_value" : "Sir Paul Beresford"}
], "uin" : "1007"}
, {"_about" : "http://data.parliament.uk/resources/348047", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/348047/answer", "answerText" : {"_value" : " Hidradenitis suppurative (HS) affects around 90,000 people in England and can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin.<\/p> <\/p> <\/p> <\/p> For those patients with the most serious forms of HS who cannot be managed through routine access treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with a involvement of a range of health and care professionals, subject to that patient\u2019s needs. More information can be found at the following link:<\/p> <\/p> <\/p> <\/p>2010<\/td> 2<\/td><\/tr> 2011<\/td> 0<\/td><\/tr> 2012<\/td> 3<\/td><\/tr> 2013<\/td> 4<\/td><\/tr> 2014<\/td> 5<\/td><\/tr><\/tbody><\/table>
<\/p>